Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 18

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 18
---
 be determined by us from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by us as to the appropriate sources of funding and our operations. Concurrent with the execution of the New Keystone Purchase Agreement, we entered into the New Keystone Registration Rights Agreement, pursuant to which we agreed to provide Keystone with customary registration rights related to the shares issued under the New Keystone Purchase Agreement. 1 Third PIPE Financing On September 25, 2024, we consummated a private placement of 2,853 shares of Series C Preferred Stock and 81,752 Series C Warrants pursuant to the Third Securities Purchase Agreement, by and among us and certain PIPE Investors for aggregate cash proceeds of approximately $1.25 million. In connection with the Third PIPE Financing, we entered into the Third PIPE Registration Rights Agreement with the PIPE Investors. The terms of the Third PIPE Registration Rights Agreement require us to register the number of shares of Common Stock equal to the sum of (i) 250% of the maximum number of Common Stock issuable upon conversion of the Series C Preferred Stock (assuming for purposes hereof that (x) the Series C Preferred Stock is convertible at the Alternate Conversion Price (as defined in the Series C Certificate of Designations) assuming an Alternate Conversion Date (as defined in the Series C Certificate of Designations) of such date of determination, and (y) any such conversion shall not take into account any limitations on the conversion of the Series C Preferred Stock set forth in the Series C Certificate of Designations) and (ii) the maximum number of Warrant Common Shares issuable upon exercise of the Warrants (without taking into account any limitations on the exercise of the Warrants set forth therein). Investigational New Drug Application On June 28, 2024, we submitted an investigational new drug application (“IND”) for its product candidate, CER-1236, to the FDA. On July 26, 2024, we were informed by the FDA that it has placed a clinical hold on the IND. The FDA indicated that the clinical hold has been placed as a result of insufficient data provided with regard to two issues within pharmacology and toxicology of CER-1236. The FDA indicated that, within 30 calendar days, it would provide a detailed official hold letter and requested that the Company hold its response until after receipt of such letter (the “Hold Letter”). The Company received the Hold Letter on July 26, 2024 and submitted a complete response